このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Nanoform Finland Oyj マネジメント

マネジメント基準チェック /24

Nanoform Finland Oyj'sの CEO はEdward Haeggstromで、 Jan2015年に任命され、の在任期間は 9.42年です。は、会社の株式の6.33%を直接所有しており、その価値は€ 9.33M 。経営陣と取締役会の平均在任期間はそれぞれ5.4年と5年です。

主要情報

Edward Haeggstrom

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	9.5yrs
CEOの所有権	6.3%
経営陣の平均在職期間	5.5yrs
取締役会の平均在任期間	5.1yrs

経営陣の近況

Recent updates

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Jan 25

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Dec 21

CEO（最高経営責任者

Edward Haeggstrom (55 yo)

9.5yrs

在職期間

Prof. Edward Olof Haeggstrom is a Co-Founder of Nanoform Finland Oy and has been its Chief Executive Officer since 2015. Prof. Haeggstrom is Scientific Advisor and the Chairman of the Board of Directors of...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Albert Haeggstrom	CFO & Director	6.5yrs	€80.37k	0.83% € 1.3m
Edward Haeggstrom	Co-Founder & CEO	9.5yrs	データなし	6.33% € 9.7m
Henri von Haartman	Director of Investor Relations	no data	データなし	データなし
Peter Hanninen	General Counsel	3.8yrs	データなし	0.12% € 184.6k
David Rowe	Head of Manufacturing	5.5yrs	データなし	データなし
Christian Jones	Chief Commercial Officer	6.5yrs	データなし	0.45% € 687.4k
Antonio Da Silva	Chief of Business Operations	1.5yrs	データなし	0.029% € 43.8k
Johanna Kause	Chief Quality Officer	less than a year	データなし	データなし
Jamie Unwin	Vice President of Strategic Insight	no data	データなし	データなし

5.5yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: NANOFHの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Albert Haeggstrom	CFO & Director	9.5yrs	€80.37k	0.83% € 1.3m
Miguel Calado	Independent Chairman of the Board	5.3yrs	€94.50k	0.076% € 116.0k
Jeanne Thoma	Independent Director	2.7yrs	€58.51k	0.026% € 40.1k
Mads Laustsen	Independent Vice Chairman of the Board	4.8yrs	€58.51k	0.026% € 40.1k

5.1yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: NANOFHの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

Nanoform Finland Oyj マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

Recent updates

First quarter 2024 earnings released: €0.09 loss per share (vs €0.06 loss in 1Q 2023)

New minor risk - Shareholder dilution

Nanoform Finland Oyj has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 21%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation

New major risk - Share price stability

Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Forecast to breakeven in 2026

Nanoform Finland Oyj to Report Nine Months, 2024 Results on Nov 22, 2024

Consensus revenue estimates fall by 31%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth

Consensus revenue estimates fall by 31%

No longer forecast to breakeven

Price target decreased by 16% to €6.00

Consensus revenue estimates decrease by 18%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate

We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate

Consensus revenue estimates fall by 37%

Price target decreased by 9.6% to €8.28

Forecast to breakeven in 2025

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj to Report Q3, 2023 Results on Nov 22, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely

Consensus revenue estimates fall by 29%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Consensus forecasts updated

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanoform signs GMP manufacturing program with TargTex following formulation success

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Consensus revenue estimates fall to €2.05m

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.14 loss in 2Q 2020)

First quarter 2021 earnings released: €0.06 loss per share (vs €0.12 loss in 1Q 2020)

Director has left the company

Nanoform Announces Completion and Final Results of Clinical Study

Nanoform Finland Oyj has completed a Follow-on Equity Offering in the amount of €40.000001 million.

Nanoform Finland Oyj to Report Q1, 2021 Results on May 27, 2021

Nanoform Finland Announces Further Positive Interim Results from Its Ongoing Clinical Study

New 90-day high: €7.73

New 90-day high: €7.40

Nanoform's Clinical Study Indicates Positive Interim Results

Nanoform Finland plc Announces First Dosing of Nanoformed Drug Successfully Accomplished

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

New 90-day high: €4.59

Nanoform Launches Technology for Biologics and Sets New Near-Term Business Target for 2021

Nanoform Finland Oyj to Report Q3, 2020 Results on Nov 27, 2020

New 90-day low: €3.91

First half earnings released

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24